MKC — McCormick & Company, Incorporated

As of 2026-08-27, sentiment is guarded: the stock is down ~20% YTD despite a Q2 FY26 earnings beat that triggered a 5.6% bounce, and Wall Street's consensus is Hold with a $58.75 average price target. Investors are waiting for regulatory clarity and evidence that organic volume growth, not just acquisitions/FX, can sustain the top line.

Reported revenue growth inflected sharply from roughly flat-to-3% YoY through FY2025 to +16.7% in both Q1 and Q2 FY2026, driven primarily by the McCormick de Mexico acquisition and a ~2.7% FX tailwind, not broad-based volume growth. Operating margins tell a more sobering story: Q1/Q2 FY2026 came in at 13.5%/14.3% versus 14.0%/14.8% in the year-ago quarters, so margin compression offset some acquisition scale. Q1 FY2026 net income was inflated by an apparent one-time $1.0B gain (EPS $3.77), so trailing EPS of $6.05 and the 9.06 P/E are not clean; normalized EPS is closer to $3.0-3.1. Free cash flow improved to ~$987M over the last four reported quarters from ~$552M in the comparable prior-year period.

On reported TTM numbers MKC looks cheap at 9.06x P/E, but that is an artifact of the Q1 FY2026 one-time gain. On the $3.086 next-fiscal-year EPS consensus, the stock trades at roughly 17.7x forward earnings, well below its 5-year average P/E of 27.7x but reasonable for a mature packaged-foods name with slow organic growth. Price/sales of 1.99x versus a 5-year average of 3.12x and a 3.65% dividend yield provide support; this is modestly attractive versus its own history, not a deep value.

At $54.54, the market is paying ~17.7x forward EPS: it is not pricing in a breakdown, but it is also not paying for much synergy upside from the Unilever transaction. If integration goes well and volume recovers, a re-rating toward the low-20s could put fair value in the mid-$60s; if the deal stalls or organic volumes weaken further, the low-$50s analyst targets become the relevant downside.

As of 2026-08-27, RSI(14) is 54.67, price is +1.28% above the 20-day SMA and +4.78% above the 50-day SMA, but -5.09% below the 200-day SMA. That is a short-term neutral-to-firm bounce inside a longer-term downtrend; there is no oversold bounce or clear breakout, so disciplined entry may wait for a reclaim of the 200-day or a retest of the 50-day support.

• Sticky grocery inflation and value-seeking consumers are pressuring organic volume growth and pricing power.
• Input cost inflation and supply-chain/logistics volatility, including regional disruptions, are squeezing margins.
• Currency movements provided a ~2.7% tailwind in Q2 FY2026 but remain a swing factor.
• UK CMA antitrust review of the Unilever Foods combination creates regulatory overhang.
• Higher-for-longer interest rates raise the cost of carrying acquisition-related debt and pressure consumer staples multiples.

• Q3 FY2026 earnings expected late September/early October 2026, with updated organic volume and integration commentary.
• Regulatory progress on the Unilever Foods deal, including UK CMA review and divestiture of overlapping brands such as Colman's.
• Completion milestones and synergy details for the McCormick de Mexico and Unilever Foods integrations.
• Potential improvement in organic volume as grocery inflation moderates.

• Unilever Foods combination fails, is delayed, or requires value-destructive divestitures.
• Reported growth is heavily inorganic; organic volumes may stay negative as consumers trade down.
• Operating margin compression from inflation, integration costs, and supply-chain disruptions.
• Balance sheet stress: current ratio is 0.781 and total debt/equity is 0.705, with more leverage likely from the pending deal.

McCormick is a solid defensive franchise with recovering free cash flow, a 3.65% yield, and a valuation below its own history, but the top-line acceleration is largely inorganic and the Unilever Foods transaction adds real regulatory and integration risk. At ~17.7x forward earnings I see modestly positive expected returns over a 12-month horizon; I lean cautiously bullish but would size for event risk.

I used a 19.0x justified P/E on the $3.09 next-fiscal-year EPS consensus. 19x is a discount to MKC's 5-year average of 27.7x to reflect slow organic growth and integration risk, but above the current 17.7x forward multiple to reflect FCF improvement, defensive positioning, and dividend support; 19.0 * 3.086 = $58.63.